Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amphastar Pharmaceuticals (AMPH) Short-term Investments: 2013-2025

Historic Short-term Investments for Amphastar Pharmaceuticals (AMPH) over the last 12 years, with Sep 2025 value amounting to $59.9 million.

  • Amphastar Pharmaceuticals' Short-term Investments rose 2.69% to $59.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $59.9 million, marking a year-over-year increase of 2.69%. This contributed to the annual value of $70.0 million for FY2024, which is 37.75% down from last year.
  • Per Amphastar Pharmaceuticals' latest filing, its Short-term Investments stood at $59.9 million for Q3 2025, which was up 36.04% from $44.1 million recorded in Q2 2025.
  • Amphastar Pharmaceuticals' Short-term Investments' 5-year high stood at $112.5 million during Q4 2023, with a 5-year trough of $8.0 million in Q3 2021.
  • Its 3-year average for Short-term Investments is $52.7 million, with a median of $54.1 million in 2025.
  • As far as peak fluctuations go, Amphastar Pharmaceuticals' Short-term Investments soared by 472.16% in 2023, and later tumbled by 38.80% in 2025.
  • Over the past 5 years, Amphastar Pharmaceuticals' Short-term Investments (Quarterly) stood at $10.3 million in 2021, then skyrocketed by 90.54% to $19.7 million in 2022, then skyrocketed by 472.16% to $112.5 million in 2023, then tumbled by 37.75% to $70.0 million in 2024, then grew by 2.69% to $59.9 million in 2025.
  • Its last three reported values are $59.9 million in Q3 2025, $44.1 million for Q2 2025, and $54.1 million during Q1 2025.